pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

Acting HHS General Counsel Bob Foster Departs Agency

Oct 9, 2026·read at Endpoints ↗RegulatoryNeutral

The acting general counsel for the U.S. Department of Health and Human Services, Bob Foster, is no longer employed by the agency.

Endpoints News attempted to reach him via his government email and received an automated reply stating he is no longer with HHS.

No further comment or replacement information was provided, and the departure was reported without details on the reason or timing.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Acting general counsel at HHS has left the department”

read at Endpoints ↗
80 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoNew data on RevMed’s Rasonque leave potential opening for other treatmentsEndpoints
  • 2h agoCity Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debutEndpoints
  • 6h agoChai Discovery signs GSK deal to make biologics with AIEndpoints
  • 6h agoViking commercial chief is out in a hurry; Gilead looks to BeOne exec for China expansionEndpoints
  • 9h agoTRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertensionEndpoints